Objective
As the life span of the population extends, the prevalence of neurodegenerative diseases is rapidly increasing representing a considerable impact for the quality of life and economy of many countries worldwide. Most of these diseases, including Amyotrophic lateral sclerosis (ALS) are currently considered as proteopathies, where some proteins (SOD1 in the case of ALS) adopt misfolded conformations prone to aggregate and cause cellular toxicity and motor neuron death. Moreover, these proteins are secreted to extracellular media contributing to the widespread of the disease in a prion-like manner, by acting as scaffolds for the misfolding of endogenous proteins when uptaken by surrounding cells. The aim of NanoALS is to bring together Neuro and Nanoscience fields to design a novel passive immunization therapy to target the misfolded SOD1 released into cerebrospinal fluid in ALS. It will be based on the systemic delivery of gold and PLGA nanoparticles functionalized with specific antibodies against the different isoforms of misfolded SOD1. These nanoconstructs will bind the different aberrantly folded SOD1 forms preventing their reuptake by neighbouring cells and blocking the cytotoxic epitopes exposed after misfolding. The multidisciplinary work program in NanoALS covers the synthesis of the functionalized nanoconstructs as well as validation of their therapeutic potential in neuronal cell lines and in the SOD1-G93A mouse model of ALS. Immunization against misfolded extracellular proteins has showed an encouraging success in ALS mouse models and in recent clinical trials with Alzheimer patients. Optimizing the delivery systems and targeting different misfolded isoforms as well as the active exploitation and dissemination strategy designed for NanoALS will maximize the benefits of these therapies both in ALS and other proteopathies.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine neurology dementia alzheimer
- medical and health sciences basic medicine immunology immunisation
- natural sciences biological sciences biochemistry biomolecules proteins
- engineering and technology nanotechnology nano-materials
- medical and health sciences basic medicine neurology amyotrophic lateral sclerosis
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF-EF-ST - Standard EF
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2016
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
50009 ZARAGOZA
Spain
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.